Table 7 Sensitivity analyses
From: Cost-effectiveness of ustekinumab in moderate to severe Crohn’s disease in Sweden
Model input | ICER | |||
|---|---|---|---|---|
Base case | Sensitivity | Ustekinumab versus adalimumab | Ustekinumab versus vedolizumab | |
Base case | Dominating | €30,282 | ||
One-way sensitivity analyses | ||||
Discount rate cost | 3% | 0% | Dominating | €24,463 |
5% | Dominating | €33,145 | ||
Discount rate health effects | 3% | 0% | Dominating | €25,946 |
5% | Dominating | €33,091 | ||
Time horizon | 60 years | 15 years | Dominating | €33,707 |
5 years | Dominating | €71,727 | ||
Treatment duration | 2 years | 5 years | Dominating | €104,952 |
Analyses of structural changes | ||||
Indirect costs | Included | Not included | Dominating | €60,779 |
Discount rate cost and health effect | 3% | 0% | Dominating | €20,961 |
5% | Dominating | €36,220 | ||
Dose escalation | Included | Not included | Dominating | €36,229 |
Resource use cost in moderate to severe health state | Doubled from base case | Dominating | €18,876 | |
Response criteria | CDAI 100 | CDAI 70 | Dominating | €38,376 |
Effect of adverse events | Included | Not included | Dominating | €30,311 |
Utilities | IBDQ to EQ-5D | Bodger et al. [20] | Dominating | €27,980 |
SF-36 to EQ-5D | Dominating | €63,188 | ||
CDAI to EQ-5D | Dominating | €26,955 | ||